TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Using CML cell lines that were either p53 WT or null (BV173 or K562/KCL22 respectively), we confirmed that the reduction of cell counts and CFC outputs, as a consequence of IDASA treatment, was dependent on WT p53 function (Fig. 3a; Supplementary Fig. 3a).